Mitochondrial amidoxime reducing component 2 (mARC2) (EC 1.7.-.-) (Molybdenum cofactor sulfurase C-terminal domain-containing protein 2) (MOSC domain-containing protein 2) (Moco sulfurase C-terminal domain-containing protein 2)
1_MGASS 6_ SSALA 11_ RLGLP 16_ ARPWP 21_ RWLGV 26_ AALGL 31_ AAVAL 36_ GTVAW 41_ RRAWP 46_ RRRRR 51_ LQQVG 56_ TVAKL 61_ WIYPV 66_ KSCKG 71_ VPVSE 76_ AECTA 81_ MGLRS 86_ GNLRD 91_ RFWLV 96_ IKEDG 101_ HMVTA 106_ RQEPR 111_ LVLIS 116_ IIYEN 121_ NCLIF 126_ RAPDM 131_ DQLVL 136_ PSKQP 141_ SSNKL 146_ HNCRI 151_ FGLDI 156_ KGRDC 161_ GNEAA 166_ KWFTN 171_ FLKTE 176_ AYRLV 181_ QFETN 186_ MKGRT 191_ SRKLL 196_ PTLDQ 201_ NFQVA 206_ YPDYC 211_ PLLIM 216_ TDASL 221_ VDLNT 226_ RMEKK 231_ MKMEN 236_ FRPNI 241_ VVTGC 246_ DAFEE 251_ DTWDE 256_ LLIGS 261_ VEVKK 266_ VMACP 271_ RCILT 276_ TVDPD 281_ TGVID 286_ RKQPL 291_ DTLKS 296_ YRLCD 301_ PSERE 306_ LYKLS 311_ PLFGI 316_ YYSVE 321_ KIGSL 326_RVGDP
1: Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles (PubMed:21029045, PubMed:24423752). As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability (PubMed:21029045, PubMed:24423752). May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis (PubMed:21029045). Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transfer from NADH to cytochrome b5 reductase then to cytochrome b5, the ultimate electron donor that primes the active site for substrate reduction (PubMed:21029045)